KLK3 and neoplasm: Here, ABDH9 hypermethylation was not found to be significantly associated with time to progression (Table 2), however in this study, progression was very broadly defined as either BCR (PSA ≥ 0.2 ng/mL), receipt of secondary treatment, positive imaging results, prostate bed or lymph node biopsy showing tumor content, diagnosis of tumor recurrence, or PC-specific death.